Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We hope to beautify the Pharmalot grounds, promenade with the official mascot, and catch up on our reading. And what about you? This is a lovely time of year to enjoy the great outdoors. Those of you who are vaccinated may have a chance to re-enter society at a favorite coffee shop. And for those who can do so, remember to reach out to Mom. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon….

Pfizer (PFE) and BioNTech (BNTX) asked the Food and Drug Administration for full approval of their Covid-19 vaccine; if approved, it would be the first shot in the U.S. to hold that distinction, NBC News says. Last December, the vaccine was the first in the U.S. to be authorized for emergency use. Full approval may make vaccine mandates more feasible and help employers decide whether to require employees get vaccinated before reentering the workplace. The FDA is expected to take several weeks to review the application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.